This study is testing a drug called remternetug for people who are at risk for, or already have, a type of early onset Alzheimer's disease caused by a genetic mutation. Researchers want to see if remternetug can help prevent or reduce the buildup of amyloid beta (Aβ) in the brain, which is thought to play a role in Alzheimer's. You would receive either remternetug or a matching placebo (an inactive substance) as an injection under the skin every 12 weeks. The study will also look at how safe remternetug is, how well people tolerate it, and its effects on disease markers like brain scans. The goal is to see if treating Alzheimer's at its earliest stages can slow down the disease's progression. The current status of this study is unclear.

Study design

This is an interventional study planning to enroll 280 participants. It compares remternetug to a placebo.

What's involved

Participants will receive subcutaneous injections of either remternetug or a placebo every 12 weeks. Brain scans ([11C]PiB-PET) will be done at the start and at Week 192.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for measuring changes in amyloid load is at Week 192 after the start of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.